Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin [2]

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 599-601

  Rodriguez, J C ^a   Garcia Pachon, E ^a   Flores, E ^a   Escribano, I ^a   Ruiz, M ^a   Royo, G ^a  

^a Hospital General Universitario   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFOXITIN; CLARITHROMYCIN; DOXYCYCLINE; IMIPENEM; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL PRACTICE; DRUG SENSITIVITY; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; NONHUMAN; RANK SUM TEST; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE;

EID: 36549048358     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.599     Document Type: Letter

References (15)

1. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003;47:1958-1962.
2. American Thoracic Society. Diagnosis and treatment of diseases caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156:S1-S25.
3. Rodriguez JC, Garcia-Pachon E, Ruiz M, Royo G. Drug susceptibility of the Mycobacterium genus: in vitro tests and clinical implications. Curr Clin Pharmacol 2006; 1:277-289.
4. Niederman MS. Principles of appropriate antibiotic use. Int J Antimicrob Agents 2005;26 (Supl 3):S170-S175.
5. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrobial Chemother 2005;56:344-348.
6. NCCLS. Susceptibility testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard. NCCLS document M24-A. NCCLS: Wayne, 2003.
7. Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: identifying drug exposures to suppress amplification of resistance mutant subpopulations. Clin Infect Dis 2006;42:525-532.
8. Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents 2003;21:585-588.
9. Baquero F. Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat 2001;4:93-105.
10. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemoter 2003;52:11-17.
11. Nash KA, Zhang Y, Brown-Elliot BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005;55:170-177.
12. Tebas P, Sultan F, Wallace RJ Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infec Dis 1995;20:443-444.
13. Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996;40:1676-1681.
14. Vemulapalli RK, Cantey JR, Steed LL, Knapp TL, Thielman NM. Emergence of resistance to clarithromycin during treatment of disseminated cutaneous Mycobacterium chelonae infection: case report and literature review. J Infect 2001;43:163-168.
15. Wallace RJ Jr, Bedsole G, Sumter G. et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990;34:65-70.